Lisata Therapeutics Inc (LTS:0HS8)
$ 3.255 0 (0%) Market Cap: 28.95 Mil Enterprise Value: -14.23 Mil PE Ratio: 0 PB Ratio: 0.67 GF Score: 37/100

Caladrius Biosciences Inc & Cend Therapeutics Definitive Merger Agreement Call Transcript

Apr 27, 2022 / 12:30PM GMT
Release Date Price: $8.55 (-10.95%)
Operator

Welcome to the Caladrius Biosciences Definitive Merger Agreement with Cend Therapeutics Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, Wednesday, April 27, 2022.

I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead, sir.

John D. Menditto
Caladrius Biosciences, Inc. - VP of IR & Corporate Communications

Thank you, operator, and good morning, everyone. Joining me today from my management team are Dr. David Mazzo, President and Chief Executive Officer; and Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer.

Earlier this morning, we issued a press release announcing the exciting news regarding our definitive merger agreement with Cend Therapeutics and proposed formation of Lisata Therapeutics. The press release, the link to this webcast and accompanying slides can be found under the Investors and News section of the Caladrius Company website. If you have not

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot